Evidence map›Paper›PMID 38264737›Full record

ArticleFrontiers in oncology2023

Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report.

Silvio Ligia, Emilia Scalzulli, Ida Carmosino, Giovanna Palumbo, Maria Chiara Molinari, Rebecca Poggiali, Alessandro Costa, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Silvio LigiaHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Emilia ScalzulliHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Ida CarmosinoHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Giovanna PalumboHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Maria Chiara MolinariHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Rebecca PoggialiHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Alessandro CostaHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Maria Laura BisegnaHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Maurizio MartelliHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I - Sapienza University, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report presents a 3-year-old female patient initially diagnosed with polycythemia vera (PV) in 2001. The patient exhibited elevated red blood cell (RBC) counts, high hemoglobin (Hb) levels, hyperleukocytosis, and moderate thrombocytosis, with sporadic abdominal pain and significant splenomegaly. Despite various treatments, including phlebotomies, hydroxyurea, and alpha-interferon, the patient struggled to maintain optimal hematocrit levels and experienced persistent symptoms. Subsequent genomic analysis revealed a rare

Indexed as

case reportJAK2 mutationspolycythemia veraRopeginterferon alfa-2byoung patient

Identifiers

PMID38264737
PMCPMC10803620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.